GSK signs ‘bubble boy disease’ agreement with MolMed

GlaxoSmithKline’s efforts to tackle a rare and often deadly immune deficiency are making progress following the announcement that they have signed a deal with Italy’s MolMed. In October last year, GSK linked up with San Raffaele Telethon Institute, gaining an exclusive licence to an investigational gene therapy for ADA-SCID (adenosine deaminase deficiency – severe combined

Continue Reading

Novartis MS pill rejected by NICE

The decision by the UK’s cost watchdog to reject Novartis’ Gilenya, the first pill to treat multiple sclerosis, has been greeted with dismay by the company and patient groups. In provisional draft guidance published this morning, the National Institute for Health and Clinical Excellence has decided against recommending payment by the National Health Service for

Continue Reading

Roche gains RoActemra European Approval for children with RA

Roche has gained approval in Europe for its biologic RoActemra for systemic juvenile idiopathic arthritis. The European Commission has approved the use of RoActemra (tocilizumab) for the treatment of active sJIA in patients two years of age and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs and systemic corticosteroids (used to

Continue Reading

AZ’s Nexium/aspirin combination gets EU thumbs-up

AstraZeneca have announced that Axanum, a fixed dose combination of 81 mg low-dose ASA (acetylsalicylic acid) and 20 mg esomeprazole, has received positive agreement for approval in 23 European Union member countries and in Norway. The combination is indicated for prevention of cardiovascular events such as heart attack or stroke, in high-risk patients in need of

Continue Reading

Quintiles takes commercial operations to Russia

US-based biopharmaceutical services company Quintiles is expanding its remit in Russia by launching its first commercial project in the market. The project involves a 40-strong sales team and comes after Quintiles set up a local legal entity to deliver commercial operations in the country and appointed Sergey Smirnov as head of business development & operations,

Continue Reading

Bristol-Myers Squibb to acquire Amira

Bristol-Myers Squibb has hit the acquisition trail again and is buying privately held Amira Pharmaceuticals in a deal that could be worth $475 million to the inflammatory and fibrotic diseases specialist. Under the terms of the agreement, B-MS is shelling out $325 million in an upfront fee and may make additional milestone payments totalling $150

Continue Reading

Roche buys German cancer diagnostics firm

Roche has signed an agreement to acquire mtm laboratories, a privately-held German in vitro diagnostics company which specialises in  early detection of cervical cancer. Under the terms of the deal, the Swiss major will pay shareholders in the Heidelberg-based group an upfront payment of around 130 million euros, plus an extra 60 million euros “upon

Continue Reading

GSK Expands Vaccine Presence in China

GlaxoSmithKline (GSK) has entered into an agreement to purchase Shenzhen Neptunus’ stake in a previously formed joint venture between the companies involved in the development and manufacture of influenza vaccines in China, Hong Kong, and Macau. GSK will pay Shenzhen Neptunus $39 million, after which GSK will be the sole owner of the joint venture

Continue Reading

Amgen has been boosted by the news that regulators in the European Union have given the green light to Xgeva for cancer-related fractures.

Amgen has been boosted by the news that regulators in the European Union have given the green light to Xgeva for cancer-related fractures. Specifically, the European Commission has granted marketing authorisation for Xgeva (denosumab) for the prevention of skeletal-related events in adults with bone metastases from solid tumours. The Commission has also granted the drug

Continue Reading